SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

berobenatide

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
If Phase 3 trials succeed, a potential FDA filing would likely occur no earlier than 2028, given that the pivotal VESPER-6 monthly maintenance trial only opened enrollment in June 2026 and obesity trials typically run 12-18 months for primary completion.
Why 4/10
No hard dated catalyst (PDUFA or pivotal readout) is scheduled within the next ~12 months; the Phase 3 program (VESPER-4, -5, -6) is still enrolling patients. For a large, diversified pharma like Pfizer, berobenatide is one of many pipeline assets, so even a major readout would move the stock by a few percent, not a binary event.
Actionable Insight NEUTRAL

The next catalysts are Phase 3 enrollment updates and any interim data from the VESPER-4, VESPER-5, or VESPER-6 trials, but no hard binary readout or PDUFA date is scheduled within the next 12 months. Positive Phase 3 data would validate the monthly-dosing thesis and could open a large market; negative data (efficacy miss or unexpected safety) would damage Pfizer's obesity strategy and the $10B Metsera acquisition thesis.

Price Chart

Loading chart...

Executive Summary

Berobenatide is Pfizer's investigational ultra-long-acting GLP-1 receptor agonist for obesity and overweight, acquired through the ~$10 billion purchase of Metsera in November 2025. Phase 2b data presented at ADA June 2026 showed up to 12.3% placebo-adjusted weight loss with monthly maintenance dosing and a side-effect profile similar to Wegovy. Pfizer has launched an ambitious Phase 3 program with 10+ planned studies (VESPER-4, -5, -6, and comorbidity trials), but these trials are still enrolling with no near-term binary readout or PDUFA date. For a diversified giant like Pfizer, berobenatide is an important pipeline asset but not a stock-swinging catalyst in the next 12 months.

How It Works

Berobenatide is a GLP-1 receptor agonist, meaning it mimics a natural hormone that tells the brain you are full, slows stomach emptying, and helps control blood sugar. It is designed to be 'ultra-long-acting' by attaching tightly to a blood protein called albumin, which keeps it from breaking down quickly. This allows patients to inject it once a month instead of once a week like current GLP-1 drugs (Wegovy, Ozempic, Zepbound).

Trial Status

Berobenatide has completed Phase 2b (VESPER-1, -2, -3) with positive results presented at ADA June 2026. The Phase 3 program is underway: VESPER-4 (weekly, obesity without T2D) started late 2025/March 2026; VESPER-5 (weekly, obesity with T2D) is ongoing; VESPER-6 (monthly maintenance, pivotal) opened for enrollment in June 2026; VESPER-OSA 1 (sleep apnea) started September 2026. Pfizer plans 10+ Phase 3 studies total.

The Two-Sided Case

▲ Bull Case4
First-in-class monthly dosing: berobenatide is the only GLP-1 RA in development designed for once-monthly maintenance, a significant convenience advantage over weekly injections that could drive adherence and market share.
Robust Phase 2b data: VESPER-1 showed ~16% non-placebo-adjusted weight loss at 32 weeks with no plateau, and VESPER-3 demonstrated weight loss was maintained when switching from weekly to monthly dosing.
Massive market opportunity: the global obesity drug market is projected to reach $190 billion by 2035, and Pfizer is committing heavily with 10+ Phase 3 studies in 2026 across obesity and comorbidities like sleep apnea and knee osteoarthritis.
Pfizer's commercial infrastructure and manufacturing scale could give berobenatide a distribution advantage over smaller competitors if approved.
▼ Bear Case4
Intense competition: Novo Nordisk's semaglutide (Wegovy/Ozempic) and Eli Lilly's tirzepatide (Zepbound/Mounjaro) already dominate the GLP-1 obesity market, which surpassed $132 billion globally in 2026. Berobenatide's 12.3% placebo-adjusted weight loss trails tirzepatide's ~15-16% in head-to-head comparisons.
Phase 3 is just beginning: the pivotal VESPER-6 monthly maintenance trial only opened enrollment in June 2026, and results are likely 12-18 months away. Phase 3 failure or a safety signal would write off Pfizer's $10B Metsera acquisition.
GI tolerability: nausea (~38%) and vomiting (~23.3%) rates in Phase 2b were similar to Wegovy, which could limit adherence despite the convenience of monthly dosing.
Pfizer faces a $18.5B patent cliff from 2027-2028 (Eliquis, Vyndaqel, Ibrance), and the Metsera acquisition is expected to be a drag on earnings through 2030, per Pfizer's own guidance.

Upcoming Catalysts

  • Phase 3 enrollment completion updates for VESPER-4, VESPER-5, and VESPER-6 trials (ongoing, no specific dates announced); potential interim data from Phase 3 program (timing uncertain, likely 2027+); SOLIS-1 Phase 2b data for the amylin combination (PF'3945) with berobenatide.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 12

Hover a chip for the title
1 pfizer.com2 pfizer.com3 pfizer.com4 fiercebiotech.com5 statnews.com6 qz.com7 techtimes.com8 healio.com9 managedhealthcareexecutive.com10 pfizer.com11 cdn.pfizer.com12 cnbc.com